Search Result
Results for "
Peptide conjugate
" in MedChemExpress (MCE) Product Catalog:
14
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P4198
-
-
-
- HY-P5334A
-
|
|
Tau Protein
|
Neurological Disease
|
|
AADvac 1 TFA is an active tau peptide vaccine for Alzheimer's disease research. AADvac 1 TFA is composed of a regulatory peptide 294KDNIKHVPGGGS 305 that drives tau oligomerization conjugated to Aplysia hemocyanin (KLH) and formulated with aluminum hydroxide .
|
-
-
- HY-P10736
-
|
|
GCGR
|
Metabolic Disease
|
|
AMG133 peptide payload is a GLP-1 agonist that can be used as a peptide linker conjugate of Maridebart cafraglutide (AMG133) (HY-164535) .
|
-
-
- HY-147021
-
|
|
ADC Linker
|
Cancer
|
|
MC-Val-D-Cit-PAB-PNP is a cleavable peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs). MC-Val-D-Cit-PAB-PNP contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-nitrophenol (PNP) group that allows the peptide to be linked to antitumor compounds.
|
-
-
- HY-106244A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-P10946
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
FAP targeting peptide-PEG2 conjugate (Example A1) is the peptide (HY-P10945) and linker conjugate of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand .
|
-
-
- HY-147050
-
-
-
- HY-147050A
-
-
-
- HY-P10741
-
-
-
- HY-164794
-
-
-
- HY-106244
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-128941
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker .
|
-
-
- HY-P1043A
-
|
|
Aminopeptidase
|
Cancer
|
|
NGR peptide Trifluoroacetatecontaining the Asn-Gly-Arg (NGR) motif. NGR peptide Trifluoroacetate binds to APN/CD13. NGR peptide Trifluoroacetate is directly conjugated to imaging agents that can be used for tumor imaging .
|
-
-
- HY-P1043
-
|
|
Aminopeptidase
|
Cancer
|
|
NGR peptide containing the Asn-Gly-Arg (NGR) motif. NGR peptide binds to APN/CD13. NGR peptide is directly conjugated to imaging agents that can be used for tumor imaging .
|
-
-
- HY-P10183
-
-
-
- HY-P99924
-
|
|
GHR
|
Others
|
|
Efpegsomatropin is a human growth hormone-Fc conjugate peptide. Efpegsomatropin can be used for various biochemical studies.
|
-
-
- HY-129360
-
|
|
ADC Linker
|
Cancer
|
|
Ala-Ala-Asn-PAB is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .
|
-
-
- HY-128937
-
|
|
Liposome
Folate Receptor (FR)
|
Cancer
|
|
EC1454 is a peptide compound with anticancer activity that targets folate receptor-expressing cancers. EC1454 is a folate-tubulysin conjugate that can be used to prepare drug delivery conjugates for targeted therapy .
|
-
-
- HY-129360A
-
|
|
ADC Linker
|
Cancer
|
|
Ala-Ala-Asn-PAB TFA is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .
|
-
-
- HY-P5888
-
|
Myr‐PKCɛ-
|
PKC
|
Inflammation/Immunology
|
|
PKCε inhibitor peptide,myristoylated (Myr‐PKC -) is a cell permeable myristic acid conjugated PKC peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs) .
|
-
-
- HY-P3669
-
-
-
- HY-P10736A
-
|
|
GCGR
|
Metabolic Disease
|
|
AMG133 peptide payload TFA is the TFA salt form of AMG133 peptide payload (HY-P10736). AMG133 peptide payload TFA is a GLP-1 agonist that can be used for synthesis of Maridebart cafraglutide (AMG133) (HY-164535) as a peptide linker conjugate .
|
-
-
- HY-164166
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Fmoc-Sar-Sar-Sar-OH is a small molecule polypeptide composed of four sarcosine residues, in which the N-terminus of the peptide chain is protected by Fmoc. Fmoc-Sar-Sar-Sar-OH can be used for peptide synthesis or synthesis of drug-peptide ligand conjugates .
|
-
-
- HY-P10184
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
CD36 Peptide P (93-110), Cys conjugated is a Cys labelled CD36 Peptide, and can block binding of CD36 to immobilized thrombospondin and partially inhibited collagen-induced platelet aggregation .
|
-
-
- HY-P10790
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Breast cancer targeting peptide 18–4 is a KRT1 receptor-targeting peptide, with a Kd of 0.98 μM. The amino acid sequence of Breast cancer targeting peptide 18–4 is WxEAAYQrFL, and it is an analogue of P160 peptide (HY-P10789). When covalently conjugated with the anticancer peptide MccJ25, Breast cancer targeting peptide 18–4 significantly increases the cellular uptake of MccJ25 in breast cancer cells and enhances its anticancer activity. The covalent conjugate exhibits IC50 values of 14.2, 20, and 25 μM against MCF-7, MDA-MB-435, and MDA-MB-435-MDR cells, respectively .
|
-
-
- HY-19813A
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition [1] .
|
-
-
- HY-P10870
-
|
|
Peptide-Drug Conjugates (PDCs)
FGFR
Apoptosis
|
Cancer
|
|
Pep1-DNP conjugate 9 is a functionalized peptide which is composed of the DNP-Hapten and the FGFR1 binding peptide. Pep1-DNP conjugate 9 exhibits good affinity to FGFR1 with KD of 5.01 μM. Pep1-DNP conjugate 9 recruits anti-DNP antibodies to the surface of FGFR1-positive cells, inhibits the FGF2-induced proliferation in rat skeletal myoblast cells, and induces apoptosis. Pep1-DNP conjugate 9 exhibits antitumor efficacy in mouse models .
|
-
-
- HY-P3815
-
|
|
Casein Kinase
|
Others
|
|
Casein Kinase 2 Substrate Peptide is a common CK2 substrate peptide. Casein Kinase 2 Substrate Peptide is synthesized with its C-terminus conjugated to 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS). Casein Kinase 2 Substrate Peptide can be used for protein kinase CK2 activity determination .
|
-
-
- HY-P10559
-
|
|
Bacterial
|
Infection
|
|
(RXR)4XB is a cell-penetrating peptide, that binds the phosphorodiamidate morpholino oligomers (PMOs), forms peptide-conjugated PMOs (PPMOs), and improves the delivery of PMO into bacterial cells. (RXR)4XB-PMO conjugate prevents the formation of biofilms, inhibits Pseudomonas aeruginosa with MIC50 of 0.5 to 16 μM, and reduces the bacterial burden in mouse acute pneumonia models .
|
-
-
- HY-169322
-
|
Mal-Exo-EVC-MMAE
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
APL-1081 (Mal-Exo-EVC-MMAE) is part of an antibody-conjugated active molecule (ADC). APL-1081 is conjugated with an ADC linker (peptide Mal-Exo-EEVC) and a potent tubulin polymerization inhibitor, MMAE (HY-15162) .
|
-
-
- HY-153395
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
PH-HG-005-5 (compound 16c) is a derivative of SN-38 (HY-13704) and can be used as Drug-Linker Conjugates for ADC. PH-HG-005-5 can conjugate to targeting peptides for ADCs synthesis .
|
-
-
- HY-P10701
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
Cancer
|
|
Q11 peptide is a β-sheet-forming peptide that plays an important role in self-assembly and targeted applications. As a scaffold peptide, Q11 peptide can display immunogenic epitopes and is widely used in peptide-based immune vaccine research. Additionally, Q11 peptide can be conjugated with MUC1 glycopeptides for the study of self-assembling, adjuvant-free MUC1 glycopeptide vaccines. Q11 peptide holds great potential for research in the field of cancer immunology .
|
-
-
- HY-P10648
-
|
HER2-targeting Peptide
|
EGFR
|
Cancer
|
|
Herceptide (HER2-targeting peptide) is a HER2-targeting peptide, and can be further conjugated to the near-infrared fluorescent dye indocyanine green (HY-D0711) (ICG) for developing theranostic agents .
|
-
-
- HY-161564
-
-
-
- HY-P10559A
-
|
|
Bacterial
|
Infection
|
|
(RXR)4XB TFA is a cell-penetrating peptide, that binds the phosphorodiamidate morpholino oligomers (PMOs), forms peptide-conjugated PMOs (PPMOs), and improves the delivery of PMO into bacterial cells. (RXR)4XB TFA-PMO conjugate prevents the formation of biofilms, inhibits Pseudomonas aeruginosa with MIC50 of 0.5 to 16 μM, and reduces the bacterial burden in mouse acute pneumonia models .
|
-
-
- HY-P10646
-
|
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
Muscle homing peptide M12 can preferentially bind to surface protein of muscle cells. Muscle homing peptide M12 mediates enhanced cellular uptake of nanoparticles (NPs) in myoblasts in vitro. Muscle homing peptide M12 is covalently conjugated to PLGA-PEG NPs via the N-terminal α-amino groups of peptides using the N-hydroxysuccinimide ester reaction .
|
-
-
- HY-P10895
-
|
|
Biochemical Assay Reagents
|
Others
|
|
HR97 TFA is a cell-penetrating peptide that can be combined with engineered melanin to prepare eye drops HR97-SunitiGel. The peptide-drug conjugate in HR97-SunitiGel can provide sustained ocular drug delivery .
|
-
-
- HY-P1116
-
PBP10
1 Publications Verification
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
PBP10 is a cell permeable and selective gelsolin-derived peptide inhibitor of formyl peptide receptor 2 (FPR2) over FPR1 . PBP10 is a 10-AA peptide with rhodamine conjugated at its N terminus, exerts bactericidal activity against gram-positive and gram-negative bacteria and limits microbial-induced inflammatory effects .
|
-
-
- HY-P1116A
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
PBP10 is a cell permeable and selective gelsolin-derived peptide inhibitor of formyl peptide receptor 2 (FPR2) over FPR1 . PBP10 is a 10-AA peptide with rhodamine conjugated at its N terminus, exerts bactericidal activity against gram-positive and gram-negative bacteria and limits microbial-induced inflammatory effects .
|
-
-
- HY-P1351
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Angiopep-2-cys is a conjugate of Angiopep-2 hydrochloride (HY-P2341) and cysteine. Angiopep-2 hydrochloride is a brain peptide vector. The conjugation of anticancer agents with the Angiopep-2 peptide vector could increase their efficacy in the treatment of brain cancer .
|
-
-
- HY-P10293
-
|
|
Thrombin
Others
|
Others
|
|
NQEQVSP, a fibrin-binding protein-derived peptide (FBP), is a factor XIIIa substrate. NQEQVSP can be recognized by factor XIII and is enzymatically conjugated into fibrin during polymerization .
|
-
-
- HY-150241
-
|
|
Liposome
|
Others
|
|
DOPE-NHS is a linker. DOPE-NHS can be used for peptides to be conjugated to exosomes and possibly other membrane-based nanoparticles. DOPE-NHS can be used for drug delivery .
|
-
-
- HY-P2218
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Cancer
|
|
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-P5877
-
|
|
PKC
|
Inflammation/Immunology
|
|
PKC(85–92),Myristoylated is a cell permeable myristic acid conjugated PKC peptide activator that enhances NO release in cultured human umbilical vein endothelial cells (HUVECs) .
|
-
-
- HY-P99527
-
|
ACC-001; PF 05236806
|
Amyloid-β
|
Neurological Disease
|
|
Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .
|
-
-
- HY-108409
-
|
Etienic acid; Testosterone-17β-carboxylic acid; 3-Oxoandrost-4-ene-17β-carboxylic acid
|
Others
|
Metabolic Disease
Cancer
|
|
Progesterone carboxylic acid (Testosterone-17β-carboxylic acid) is an androstenedione analogue. Progesterone carboxylic acid can conjugate with 20-mer peptide nucleic acid (PNA) and the conjugate has superior binding capacity on complementary DNA. Progesterone carboxylic acid can be used for cancers and type 2 diabetes (T2D) research
|
-
-
- HY-43869
-
|
PSMA-617 Ligand-Linker conjugate
|
ADC Linker
|
Cancer
|
|
Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA) .
|
-
-
- HY-P10444
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Cancer
|
|
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-P4091A
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
LSD acetate is a peptide. LSD acetate can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD acetate can reduce the number of tumor lymphatics. LSD acetate can be used in the research of targeted therapy and diagnosis of tumor lymphatics .
|
-
-
- HY-P4091
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics .
|
-
- HY-158199
-
|
|
ADC Linker
|
Cancer
|
|
BCN-HS-PEG2-bis(PNP) (Compound 62) is a p-nitrophenyl-containing ADC linker that can be used to further couple ADC cytotoxins with peptide linkers. BCN-HS-PEG2-bis(PNP) can conjugate with vc-PABC-MMAE (HY-15162) to form Drug-Linker Conjugates for ADC .
|
-
- HY-100566
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .
|
-
- HY-P11205
-
|
Cys-txCD47
|
CD47
Reactive Oxygen Species (ROS)
Thrombopoietin Receptor
|
Inflammation/Immunology
Cancer
|
|
Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca + accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death .
|
-
- HY-P5439
-
|
|
PKC
MARCKS
|
Others
|
|
Epsilon-V1-2, Cys-conjugated is a biological active peptide. (This peptide is the εPKC specific inhibitor. Its inhibitory activity is based on εPKC translocation and MARCKS phosphorylation. This peptide interferes with εPKC interaction with the anchoring protein εRACK. This peptide contains a cysteine residue added to the C-terminus for potential S-S bond formation with a carrier protein.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)
|
-
- HY-101909
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-PAB-MMAF is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAF contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)
|
-
- HY-15938
-
|
|
Fluorescent Dye
|
Others
|
|
5-FAM SE is a single isomer, is a fluorescent labeling reagent used for labeling peptides, proteins and nucleotides. 5-FAM SE can react with amines and can yield stable amine conjugates .
|
-
- HY-44177
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-PAB-MMAF sodium is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)
|
-
- HY-P4154
-
|
ALM-488
|
Fluorescent Dye
|
Neurological Disease
Cancer
|
|
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
|
-
- HY-172273B
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG5000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG5000-M2pep can be used for drug delivery .
|
-
- HY-172273A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG2000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG2000-M2pep can be used for drug delivery .
|
-
- HY-172273
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG1000-M2pep can be used for drug delivery .
|
-
- HY-W738256
-
|
MDTPA
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Maleimide-DTPA (MDTPA) is a monoreactive DTPA derivative (MDTPA) with maleimide group as peptide binding site, which can be combined with radionuclides to prepare radionuclide conjugates (RDC). Maleimide-DTPA can chelate indium-111 (111In) and label peptides and peptides with indium-111. For example, it has high stability when combined with OST7 incubated in human serum, which is better than cyclic cDTPA. Maleimide-DTPA is a good material for medical imaging or treatment.
|
-
- HY-172273C
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG3400-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG3400-M2pep can be used for drug delivery .
|
-
- HY-P99565
-
|
ARENEGYR; NGR-TNF; NGR-hTNF
|
TNF Receptor
|
Cancer
|
|
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment .
|
-
- HY-P10773
-
-
- HY-147239
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-VA-PABC-MMAE is a agent-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .
|
-
- HY-13631E
-
Deruxtecan
Maximum Cited Publications
18 Publications Verification
MC-GGFG-DXD
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
|
-
- HY-P10786
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
LinTT1 peptide is a tumor-penetrating peptide with the amino acid sequence AKRGARST. LinTT1 peptide targets peritoneal carcinoma (PC) by binding to the p32 (gC1qR) receptor. It can conjugate with iron oxide nanoworms (NWs) to form a nanocarrier. This nanocarrier is taken up by peritoneal carcinoma cells in vitro and enters the mitochondria; it also exhibits significant tumor targeting and penetration effects in mice. Moreover, LinTT1-functionalized nanocarriers, combined with the pro-apoptotic peptide [D(KLAKLAK)2], show significant tumor suppression in a mouse peritoneal tumor model. LinTT1 peptide holds promise as a delivery carrier for peritoneal cancer research .
|
-
- HY-P99881
-
|
ABBV 176
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Rolinsatamab talirine (ABBV 176) is an antibody-drug conjugate (ADC) targeting prolactin receptor (PRLR). Rolinsatamab talirine consists of rolinsatamab (HY-P99238), an enzymatically cleavable peptide linker, and SGD-1882 (HY-101127) .
|
-
- HY-P10757
-
-
- HY-153549
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Others
|
|
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium ( 68Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P1188
-
|
|
Integrin
|
Cancer
|
|
LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC can be used to detect α4β1 integrin affinity .
|
-
- HY-P5891
-
|
|
PKC
|
Cardiovascular Disease
|
|
TAT-SAMβA is the peptide consist of RNAENFDRF (SAMβA; HY-P3429) conjugated to the cell penetrating TAT protein-derived peptide TAT47–57. TAT-SAMβA is a selective antagonist of Mfn1-βIIPKC association. TAT-SAMβA protects mouse embryonic fibroblast cells (MEFs) against oxidative stress-induced cytotoxicity .
|
-
- HY-100374
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
|
-
- HY-P5320
-
|
|
Apoptosis
|
Others
|
|
TAT-BH4 (Bcl-xL) localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 can be used for research of diseases caused by accelerated apoptosis .
|
-
- HY-P1188A
-
|
|
Integrin
|
Cancer
|
|
LDV-FITC TFA, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC TFA binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC TFA can be used to detect α4β1 integrin affinity .
|
-
- HY-172270D
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-172270C
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-172270
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-172270A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-147286
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Ac-Lys-Val-Cit-PABC-MMAE is a agent-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .
|
-
- HY-D2760
-
|
|
Fluorescent Dye
|
Others
|
|
BP Fluor 488 acid is a powerful labeling dye. It will react with the amine group in antibody, proteins, peptides, amino-modified oligos, and other target molecules. The dye has an excitation peak at 499 nm and an emission peak at 520 nm. The conjugates are widely used in microscopy, flow cytometry, and other applications.
|
-
- HY-P10792
-
|
|
EGFR
|
Cancer
|
|
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .
|
-
- HY-132604A
-
|
ARO-AAT sodium
|
Small Interfering RNA (siRNA)
|
Metabolic Disease
|
|
Fazirsiran sodium is a second-generation RNAi agent. Fazirsiran sodium consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran sodium can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.
|
-
- HY-132604
-
|
ARO-AAT
|
Small Interfering RNA (siRNA)
|
Metabolic Disease
|
|
Fazirsiran (ARO-AAT) is a second-generation RNAi agent. Fazirsiran consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.
|
-
- HY-W071967
-
|
|
ADC Linker
|
Cancer
|
|
Alloc-Val-Ala-PAB is a peptide cleavable linker used in the synthesis of antibody-drug conjugates (ADCs). The Val-Ala will specifically be cleaved by Cathepsin B. The Alloc group is stable to treatment with piperidine and TFA, but can be easily removed under mild conditions by palladium catalyzed allyl transfer.
|
-
- HY-D2760A
-
|
|
Fluorescent Dye
|
Others
|
|
BP Fluor 488 acid triTEA is a powerful labeling dye. It will react with the amine group in antibody, proteins, peptides, amino-modified oligos, and other target molecules. The dye has an excitation peak at 499 nm and an emission peak at 520 nm. The conjugates are widely used in microscopy, flow cytometry, and other applications.
|
-
- HY-145663
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a agent-linker (peptide-cleavable) conjugate for ADC. DM indicates the maytansinoid moiety .
|
-
- HY-P5021
-
|
c(RGDfE)
|
Biochemical Assay Reagents
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) (c(RGDfE)) is a cyclic RGD peptide that serves as a conjugated multifunctional nanodrug delivery system to target Gemcitabine to pancreatic cancer cells. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) can be used in cancer research .
|
-
- HY-P5320A
-
|
|
Apoptosis
|
Others
|
|
TAT-BH4 (Bcl-xL) TFA is localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 TFA can be used for research of diseases caused by accelerated apoptosis .
|
-
- HY-P3732
-
|
|
Integrin
|
Cancer
|
|
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .
|
-
- HY-13631ES4
-
-
- HY-P4095
-
|
|
CXCR
|
Cancer
|
|
NoxaBH3 is a cysteine-based cross-linked peptide with increased cell permeability and higher inhibitory activity against Mcl-1. NoxaBH3 binds to the endogenous CXCR4 ligand to produce ubiquitin-Noxabh3 conjugate. NoxaBH3 is then delivered to cancer cells .
|
-
- HY-164535
-
|
AMG 133
|
Antibody-Drug Conjugates (ADCs)
GLP Receptor
|
Metabolic Disease
|
|
Maridebart cafraglutide (AMG 133) is an antibody-peptide conjugate acting as a GLP-1 receptor agonist and an antagonist of the GIP receptor. Maridebart cafraglutide reduces body weight and improve metabolic markers in male obese mice and cynomolgus monkeys. Maridebart cafraglutide is promising for research of obesity .
|
-
- HY-13631ES
-
-
- HY-N15721
-
|
Trp-CA
|
Orphan GPCR
|
Metabolic Disease
|
|
Tryptophan-cholic acid (Trp-CA) is a microbial amino-acid-conjugated bile acid, serving as an endogenous ligand and agonist of the orphan G protein-coupled receptor (GPCR) MRGPRE. Tryptophan-cholic acid activates MRGPRE, promoting the secretion of glucagon-like peptide-1 (GLP-1) through the Gs-cAMP and β-arrestin-1-ALDOA signaling pathways, thereby improving glucose tolerance in diabetic mice. Tryptophan-cholic acid is promising for research of type 2 diabetes .
|
-
- HY-P3429
-
|
|
PKC
|
Cardiovascular Disease
|
|
SAMβA is conjugated to the cell permeable peptide TAT47-57. SAMβA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats .
|
-
- HY-147286A
-
-
- HY-P10782
-
|
|
Peptide-Drug Conjugates (PDCs)
|
Cancer
|
|
Pt(IV)-M13 is a BBB-penetrable Platinum (IV) prodrug-perfluoroaryl macrocyclic peptide conjugate. Pt(IV)-M13 is cytotoxic to glioma stem cells and increases uptake of platinum in the brain. Pt(IV)-M13 can be used in the study of glioblastoma .
|
-
- HY-13631ES3
-
|
MC-GGFG-DXD-d2
|
Drug-Linker Conjugates for ADC
Isotope-Labeled Compounds
|
Others
|
|
Deruxtecan-d2 is the deuterium labeled Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
- HY-D2763
-
|
|
Fluorescent Dye
|
Others
|
|
BP Fluor 532 maleimide is a photostable, bright yellow-fluorescent dye with pH insensitive emission from pH 4 to pH 10. The excitation of BP Fluor 532 is ideally suited for the frequency-doubled Nd:YAG laser line. BP Fluor 532 dye can be conjugated to a variety of antibodies, peptides, proteins, tracers, and amplification substrates, and is often used for the generation of stable signals in imaging and flow cytometry.
Maleimide is the most popular sulfhydryl-reactive group for conjugating the dye to a thiol group on a protein, oligonucleotide thiophosphate, or low molecular weight ligand. The maleimide group specifically and efficiently reacts with reduced thiols (sulfhydryl groups, –SH) at pH 6.5 to 7.5 to form a stable thioether bond. The resulting conjugates exhibit brighter fluorescence and greater photostability than the conjugates of many other spectrally similar fluorophores.
|
-
- HY-147270
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-VA-PAB-Exatecan is a agent-linker conjugate for ADC. MC-VA-PAB-Exatecan contains the ADC linker (peptide MC-VA-PAB) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). MC-VA-PAB-Exatecan synthesized ADC shows good antitumor activity .
|
-
- HY-155470
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
IMP 243 is a symmetric di-HSG (histamine-succinyl-glycine) bivalent hapten containing a Tscg-Cys ligand and two HSG groups. IMP 243 can be radiolabeled with 99mTc-pertechnetate. IMP 243 can be conjugated to other peptides to design bispecific antibodies (bsMAbs) for cancer research .
|
-
- HY-13631ES2
-
|
MC-GGFG-DXD-d4-1
|
Drug-Linker Conjugates for ADC
Isotope-Labeled Compounds
|
Others
|
|
Deruxtecan-d4-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
- HY-125586
-
|
|
DNA/RNA Synthesis
ADC Payload
|
Cancer
|
|
β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic RNA polymerase II and III. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .
|
-
- HY-W729138
-
|
|
ADC Linker
|
Others
|
|
Fmoc-D-homoArg(Et)2-OH (hydrochloride) is a Fmoc-protected derivative of D-Homoarginine (HArg) that renders peptides and proteins resistant to proteolysis by trypsin. Fmoc-D-homoArg(Et)2-OH (hydrochloride) can be used as a cleavable ADC linker to synthesize antibody-drug conjugates (ADCs) .
|
-
- HY-P10762
-
|
CBP-1008; LDC 10B
|
Peptide-Drug Conjugates (PDCs)
Folate Receptor (FR)
TRP Channel
|
Cancer
|
|
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
|
-
- HY-138298
-
|
DS-8201 (solution); DS-8201a (solution)
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
|
-
- HY-138298A
-
|
DS-8201; DS-8201a
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
|
-
- HY-P3429A
-
|
|
PKC
|
Cardiovascular Disease
|
|
SAMβA TFA is conjugated to the cell permeable peptide TAT47-57. SAMβA TFA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA TFA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats .
|
-
- HY-P10775
-
|
|
Peptide-Drug Conjugates (PDCs)
MMP
|
Cancer
|
|
BT1769 is a MT1-MMP-targeted (KD = 3.35 nM) Bicycle toxin conjugate. BT1769 can be used in the study for osteosarcoma. BT1769 consists of a novel bicyclic targeting peptide that selectively binds MT1-MMP; a cytotoxin MMAE; and an enzymatically cleavable dipeptide linker .
|
-
- HY-P10307
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Bacterial
|
Infection
|
|
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ 68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-132164
-
|
|
ADC Payload
Topoisomerase
|
Cancer
|
|
Gly-7-MAD-MDCPT (compound 4b) is an anticancer agent. Gly-7-MAD-MDCPT is a Camptothecin (HY-16560) compound, it shows cytotoxicity to various cancer cells with IC50 values of 10-1000 nM .
|
-
- HY-132164A
-
|
|
ADC Payload
Topoisomerase
|
Cancer
|
|
Gly-7-MAD-MDCPT (Compound 4b) hydrochloride is an anticancer agent. Gly-7-MAD-MDCPT hydrochloride is a Camptothecin (HY-16560) compound, which shows cytotoxicity to various cancer cells with IC50 values of 10-1000 nM .
|
-
- HY-132164B
-
|
|
ADC Payload
Topoisomerase
|
Cancer
|
|
Gly-7-MAD-MDCPT (Compound 4b) TFA is an anticancer agent. Gly-7-MAD-MDCPT TFA is a Camptothecin (HY-16560) compound, which shows cytotoxicity to various cancer cells with IC50 values of 10-1000 nM .
|
-
- HY-P5297
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Cancer
|
|
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
-
- HY-P10846
-
|
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
|
HYNIC-CTP is a conjugate of HYNIC and CTP (cardiac-targeting peptide). HYNIC-CTP can bind with the radionuclide 99mTc through HYNIC acting as a chelator, forming 99mTc-HYNIC-CTP. 99mTc-HYNIC-CTP is specifically taken up by the heart and used for cardiac imaging, thereby facilitating research into heart diseases .
|
-
- HY-P6351
-
|
|
Integrin
|
Cancer
|
|
c(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with DOTA chelator. The Lu(III) complex of c(avb6)-DOTA TFA has a comparable affinity for αvβ6 integrin (IC50=0.8 nM) and can be used as a tumor diagnostic .
|
-
- HY-100374G
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
|
-
- HY-164165
-
|
|
Microtubule/Tubulin
Drug Derivative
|
Cancer
|
|
Paclitaxel-2′-succinate NHS ester is a paclitaxel derivative with a succinic acid linker, in which the carboxyl group is activated by the NHS ester. The NHS ester group is highly reactive toward amino or hydroxyl groups and can be used to conjugate with other molecules such as peptides, proteins, antibodies, enzymes or polymers. Paclitaxel-2′-succinate NHS ester can be used in the development of nanomedicines and in the study of cancer therapy .
|
-
- HY-P10740
-
|
|
Peptide-Drug Conjugates (PDCs)
Antifolate
|
Cancer
|
|
CBP-1018 is a PDC (peptide drug conjugate) consisting of a dual targeting FRα/prostate-specific membrane antigen (PSMA) ligand (blue part) coupled to Monomethyl auristatin E (HY-15162) (red part) via a linker (HY-78738) (black part). CBP-1018 is expected to be used in breast cancer research .
|
-
- HY-P10770
-
|
|
Peptide-Drug Conjugates (PDCs)
E-Selectin
|
Cardiovascular Disease
Cancer
|
|
P-ESBP-DOX is a HPMA copolymer-drug conjugate, which is consistituted of the E-selectin binding peptide and the Doxorubicin (HY-15142). P-ESBP-DOX exhibits cytotoxicity against TNFα-activated human vascular endothelial cells IVECs with an IC50 of 0.28 μM. P-ESBP-DOX can be used in research about tumor vasculature .
|
-
- HY-W074648
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 18 is a multi-arm AIE molecule extracted from patent CN110123801A, compound 23. Antibacterial agent 18 can be used for resisting Gram-positive and Gram-negative bacteria. Antibacterial agent 18 can be conjugated in the cell wall of rigid arm configuration insertion bacterium, and block cell wall turns sugar and turns peptide process, to inhibit or kill bacterium .
|
-
- HY-P10760
-
|
|
Peptide-Drug Conjugates (PDCs)
|
Cancer
|
PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .
|
-
- HY-P10356
-
|
|
TRP Channel
|
Others
|
|
T100-Mut is a cell-permeable peptide whose N-terminus is conjugated with a myristoylated group to enable T100-Mut to penetrate and localize to the inner side of the plasma membrane, thus mimicking the topology of Tmem100-3Q. T100-Mut can alleviate TRPA1-mediated pain .
|
-
- HY-15582
-
|
|
Microtubule/Tubulin
ADC Payload
|
Cancer
|
|
Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .
|
-
- HY-W614269
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Others
|
|
DOTA-GA(tBu)4 is a DOTA derivative similar to NOTA-GA. DOTA-GA(tBu)₄ is a tert-butyl-protected chelating agent used for the synthesis of DOTA-GA-TATE conjugates. The structure of DOTA-GA(tBu)4 allows for convenient conjugation to the N-terminus of peptides. DOTA-GA(tBu)4 can be used in research on medical imaging and diagnosis .
|
-
- HY-P4073
-
|
GRN1005; Paclitaxel trevatide
|
Peptide-Drug Conjugates (PDCs)
LDLR
|
Cancer
|
|
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .
|
-
- HY-153486
-
|
|
Biochemical Assay Reagents
|
Others
|
|
N3-VC-PAB-PNP is the intermediate of bicyclic peptide ligand STING conjugates . N3-VC-PAB-PNP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-13631EG
-
|
MC-GGFG-DXD
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
|
-
- HY-W800702
-
|
|
Fluorescent Dye
|
Others
|
|
BP Fluor 555 Azide is a water-soluble, bright orange-fluorescent dye with excitation ideally suited for the 532 nm or 555 nm laser lines and visualized with TRITC (tetramethylrhodamine) filter sets. BP Fluor 555 conjugates of antibodies, peptides, and proteins are pH insensitive from pH 4 to pH 10. AF 555 conjugates ideally suited for detection of low abundance targets.
BP Fluor 555 Azide can be reacted with terminal alkynes via a copper-catalyzed click reaction (CuAAC). It also reacts with strained cyclooctyne via a copper-free “click chemistry” reaction to form a stable triazole and does not require Cu-catalyst or elevated temperatures. The brightness and photostability of this dye are best suited to direct imaging of low-abundance targets.
|
-
- HY-164992
-
|
MRG002; Trastuzumab MMAE
|
Antibody-Drug Conjugates (ADCs)
EGFR
Microtubule/Tubulin
|
Cancer
|
|
Trastuzumab vedotin (MRG002) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab vedotin is composed of a humanized anti-HER2 antibody Trastuzumab (HY-P9907), an enzymatically cleavable peptide-linker Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE; HY-15162). Trastuzumab vedotin can be used for the research of HER2-positive breast cancer .
|
-
- HY-W800680
-
|
|
Fluorescent Dye
|
Others
|
|
BP Fluor 488 DBCO is a popular labeling dye used in copper-free Click Chemistry reactions. It will react with the azide group in antibody, proteins, peptides, amino-modified oligos, and other target molecules. The dye has an excitation peak at 499 nm and an emission peak at 520 nm. The conjugates are widely used in microscopy, flow cytometry, and other applications. BP Fluor 488 is a pure 5-sulfonated rhodamine molecule and it eliminates the lot-to-lot variation caused by two isomers ratio differences.
|
-
- HY-W781921
-
|
|
Fluorescent Dye
|
Others
|
|
BP Fluor 488 Alkyne is a popular labeling dye used in Click Chemistry reactions. It will react with the azide group in antibody, proteins, peptides, amino-modified oligos, and other target molecules. The dye has an excitation peak at 499 nm and an emission peak at 520 nm. The conjugates are widely used in microscopy, flow cytometry, and other applications. BP Fluor 488 is a pure 5-sulfonated rhodamine molecule and it eliminates the lot-to-lot variation caused by two isomers ratio differences.
|
-
- HY-140739
-
|
|
Liposome
|
Neurological Disease
Cancer
|
|
DSPE-PEG2000-Maleimide is a phospholipid-PEG conjugate. DSPE-PEG2000-Maleimide utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles. DSPE-PEG2000-Maleimide covalently couples to the sulfhydryl (-SH) of ligands (such as antibodies, peptides, or proteins) via thiol-maleimide click chemistry, giving the particles targeting capabilities. DSPE-PEG2000-Maleimide can be used in the researches of breast cancer, lymphoma, and inherited retinal degeneration .
|
-
- HY-P4742A
-
|
6-FAM-AEEAC-SHK TFA
|
Biochemical Assay Reagents
Potassium Channel
|
Neurological Disease
|
|
6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA (6-FAM-AEEAC-SHK TFA) is a peptide neurotoxin conjugated with a fluorescent marker. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can block voltage-gated potassium channels (kv1.1 and kv1.2) to prolong the duration of action potentials, thereby affecting the conduction of neural signals. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can be used in neuroscience research .
|
-
- HY-D2745
-
|
|
Fluorescent Dye
|
Others
|
|
BP Fluor 594 NHS ester is the most popular tool for modifying proteins or antibodies through the primary amines (Lys), amine-modified oligonucleotides, and other amine-containing biomolecules with BP Fluor 594 label. The labeling occurs most efficiently at pH 7-9 and forms a stable, covalent amide bond. BP Fluor 594 dye can be used for proteins labeling at high molar ratios without significant self-quenching, enabling brighter conjugates and more sensitive detection.
BP Fluor 594 is bright, water-soluble, and pH-insensitive from pH 4 to pH 10 red-fluorescent dye with absorption and emission maxima at 590 and 617 nm, respectively. It can be used with the 561 nm and 594 nm laser lines. BP Fluor 594 dye conjugated to a variety of antibodies, peptides, proteins, tracers, and amplification substrates often used for generation of stable signal in imaging and flow cytometry.
|
-
- HY-140739A
-
|
|
Liposome
|
Neurological Disease
Cancer
|
|
DSPE-PEG2000-Maleimide free acid is a phospholipid-PEG conjugate. DSPE-PEG2000-Maleimide free acid utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles. DSPE-PEG2000-Maleimide free acid covalently couples to the sulfhydryl (-SH) of ligands (such as antibodies, peptides, or proteins) via thiol-maleimide click chemistry, giving the particles targeting capabilities. DSPE-PEG2000-Maleimide free acid can be used in the researches of breast cancer, lymphoma, and inherited retinal degeneration .
|
-
- HY-P10947
-
|
|
Epigenetic Reader Domain
YAP
|
Cancer
|
|
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 + tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .
|
-
- HY-P10761
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Carbonic Anhydrase
|
Cancer
|
|
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC50 for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-115693
-
|
|
Bacterial
|
Infection
|
|
CAP 3 is a cholic acid-peptide conjugate (CAP) antimicrobial agent. CAP 3 effectively inhibits Gram-negative bacteria, with MIC99 (minimum inhibitory concentration for 99% bacterial killing) values of 8 μM, 16 μM, and 16 μM against E. coli, Klebsiella pneumoniae and Acinetobacter baumannii, respectively. CAP 3 exerts its antibacterial effects by disrupting the structural integrity of the bacterial lipopolysaccharide (LPS) outer membrane. CAP 3 rapidly kills bacteria, inhibits biofilm formation, and effectively combats drug-resistant strains and persistent bacterial infections .
|
-
- HY-D2747
-
|
|
Fluorescent Dye
|
Others
|
|
BP Fluor 405 acid is a water-soluble, blue-fluorescent dye that is often used in multi-color applications, including flow cytometry and super-resolution microscopy using STORM. Its excitation is ideally suited for the 407 nm spectral line of the krypton laser or the 408 nm violet laser diode. BP Fluor 405 conjugates are pH-insensitive from pH 4 to pH 10.
The carboxylic acid of BP Fluor 405 is a reagent of choice for the preparation of custom activated esters that often are not commercially available. Examples of such activated esters include sulfo-NHS, TFP (2,3,5,6-Tetrafluorophenol), and STP (4-Sulfo-2,3,5,6-Tetrafluorophenol, Sodium Salt). Another common application for the non-activated carboxylic acid is peptide modification during solid phase synthesis, which usually requires in-situ activation with peptide coupling regents, e.g. HATU. BP Fluor 405 acid is also often used for control experiments, and for calibration.
|
-
- HY-P10446
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Epigenetic Reader Domain
|
Cancer
|
|
TAT-PiET-PROTAC is a proteolysis-targeting chimera (PROTAC)-modified TAT-PiET (HY-P10445). TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4. TAT-PiET-PROTAC can disrupt the interaction between the breast cancer oncogene BRD4/JMJD6 and inhibit the growth of breast cancer cells. TAT-PiET-PROTAC also resists the endocrine resistance of ERα-positive breast cancer cells and is a potential inhibitor of breast cancer . TAT-PiET-PROTAC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-D2738
-
|
|
Fluorescent Dye
|
Others
|
|
BP Fluor 532 NHS ester is an amine reactive, yellow-emitting dye routinely used to label proteins or antibodies through primary amines (Lys), amine-modified oligonucleotides, and other amine-containing biomolecules. The labeling occurs most efficiently at pH 7-9 and forms a stable, covalent amide bond.
BP Fluor 532 is a bright yellow-fluorescent dye with pH insensitive emission from pH 4 to pH 10. The excitation of BP Fluor 532 is ideally suited for the frequency-doubled Nd:YAG laser line. BP Fluor 532 can be conjugated to a variety of antibodies, peptides, proteins, tracers, and amplification substrates, and is often used for the generation of stable signals in imaging and flow cytometry.
|
-
- HY-P11018
-
|
|
Peptide-Drug Conjugates (PDCs)
Ephrin Receptor
|
Cancer
|
|
(123B9)2-L2-PTX is an EphA2-agonistic peptide-drug conjugate (PDC). (123B9)2-L2-PTX consists of a dimeric 123B9 (HY-P10579) and Paclitaxel (HY-B0015). (123B9)2-L2-PTX significantly reduces circulating tumor cells and inhibits lung tumor metastasis in breast-cancer-Metastasis mice model. (123B9)2-L2-PTX can be used for cancers research, such as melanomas and ovarian and breast cancers .
|
-
- HY-W800701
-
|
|
Biochemical Assay Reagents
|
Others
|
|
BP Fluor 546 DBCO is an azide-reactive probe that can be used for imaging azide-tagged biomolecules via a copper-free click reaction. The DBCO moiety reacts with azides to form a stable triazole and does not require a Cu-catalyst or elevated temperatures. In applications where the presence of copper is a concern, BP Fluor 546 DBCO is an ideal alternative to copper-requiring fluorescent alkynes.
BP Fluor 546 is a water-soluble, pH-insensitive (from pH 4-10), orange-fluorescent dye with absorption and emission maxima at 554 and 570 nm, respectively. It can be used with the 488 nm and 532 nm laser lines. BP Fluor 546 dye conjugates to a variety of antibodies, peptides, proteins, tracers, and amplification substrates, which are often used for generating stable signals in imaging and flow cytometry.
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-15938
-
|
|
Fluorescent Dyes/Probes
|
|
5-FAM SE is a single isomer, is a fluorescent labeling reagent used for labeling peptides, proteins and nucleotides. 5-FAM SE can react with amines and can yield stable amine conjugates .
|
-
- HY-D2760
-
|
|
Fluorescent Dyes/Probes
|
|
BP Fluor 488 acid is a powerful labeling dye. It will react with the amine group in antibody, proteins, peptides, amino-modified oligos, and other target molecules. The dye has an excitation peak at 499 nm and an emission peak at 520 nm. The conjugates are widely used in microscopy, flow cytometry, and other applications.
|
-
- HY-D2760A
-
|
|
Fluorescent Dyes/Probes
|
|
BP Fluor 488 acid triTEA is a powerful labeling dye. It will react with the amine group in antibody, proteins, peptides, amino-modified oligos, and other target molecules. The dye has an excitation peak at 499 nm and an emission peak at 520 nm. The conjugates are widely used in microscopy, flow cytometry, and other applications.
|
-
- HY-D2763
-
|
|
Fluorescent Dyes/Probes
|
|
BP Fluor 532 maleimide is a photostable, bright yellow-fluorescent dye with pH insensitive emission from pH 4 to pH 10. The excitation of BP Fluor 532 is ideally suited for the frequency-doubled Nd:YAG laser line. BP Fluor 532 dye can be conjugated to a variety of antibodies, peptides, proteins, tracers, and amplification substrates, and is often used for the generation of stable signals in imaging and flow cytometry.
Maleimide is the most popular sulfhydryl-reactive group for conjugating the dye to a thiol group on a protein, oligonucleotide thiophosphate, or low molecular weight ligand. The maleimide group specifically and efficiently reacts with reduced thiols (sulfhydryl groups, –SH) at pH 6.5 to 7.5 to form a stable thioether bond. The resulting conjugates exhibit brighter fluorescence and greater photostability than the conjugates of many other spectrally similar fluorophores.
|
-
- HY-100374G
-
|
|
Fluorescent Dye
|
|
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
|
-
- HY-13631EG
-
|
MC-GGFG-DXD (GMP)
|
Fluorescent Dye
|
|
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
|
-
- HY-W800702
-
|
|
Fluorescent Dyes/Probes
|
|
BP Fluor 555 Azide is a water-soluble, bright orange-fluorescent dye with excitation ideally suited for the 532 nm or 555 nm laser lines and visualized with TRITC (tetramethylrhodamine) filter sets. BP Fluor 555 conjugates of antibodies, peptides, and proteins are pH insensitive from pH 4 to pH 10. AF 555 conjugates ideally suited for detection of low abundance targets.
BP Fluor 555 Azide can be reacted with terminal alkynes via a copper-catalyzed click reaction (CuAAC). It also reacts with strained cyclooctyne via a copper-free “click chemistry” reaction to form a stable triazole and does not require Cu-catalyst or elevated temperatures. The brightness and photostability of this dye are best suited to direct imaging of low-abundance targets.
|
-
- HY-W800680
-
|
|
Fluorescent Dyes/Probes
|
|
BP Fluor 488 DBCO is a popular labeling dye used in copper-free Click Chemistry reactions. It will react with the azide group in antibody, proteins, peptides, amino-modified oligos, and other target molecules. The dye has an excitation peak at 499 nm and an emission peak at 520 nm. The conjugates are widely used in microscopy, flow cytometry, and other applications. BP Fluor 488 is a pure 5-sulfonated rhodamine molecule and it eliminates the lot-to-lot variation caused by two isomers ratio differences.
|
-
- HY-D2745
-
|
|
Fluorescent Dyes/Probes
|
|
BP Fluor 594 NHS ester is the most popular tool for modifying proteins or antibodies through the primary amines (Lys), amine-modified oligonucleotides, and other amine-containing biomolecules with BP Fluor 594 label. The labeling occurs most efficiently at pH 7-9 and forms a stable, covalent amide bond. BP Fluor 594 dye can be used for proteins labeling at high molar ratios without significant self-quenching, enabling brighter conjugates and more sensitive detection.
BP Fluor 594 is bright, water-soluble, and pH-insensitive from pH 4 to pH 10 red-fluorescent dye with absorption and emission maxima at 590 and 617 nm, respectively. It can be used with the 561 nm and 594 nm laser lines. BP Fluor 594 dye conjugated to a variety of antibodies, peptides, proteins, tracers, and amplification substrates often used for generation of stable signal in imaging and flow cytometry.
|
-
- HY-D2747
-
|
|
Fluorescent Dyes/Probes
|
|
BP Fluor 405 acid is a water-soluble, blue-fluorescent dye that is often used in multi-color applications, including flow cytometry and super-resolution microscopy using STORM. Its excitation is ideally suited for the 407 nm spectral line of the krypton laser or the 408 nm violet laser diode. BP Fluor 405 conjugates are pH-insensitive from pH 4 to pH 10.
The carboxylic acid of BP Fluor 405 is a reagent of choice for the preparation of custom activated esters that often are not commercially available. Examples of such activated esters include sulfo-NHS, TFP (2,3,5,6-Tetrafluorophenol), and STP (4-Sulfo-2,3,5,6-Tetrafluorophenol, Sodium Salt). Another common application for the non-activated carboxylic acid is peptide modification during solid phase synthesis, which usually requires in-situ activation with peptide coupling regents, e.g. HATU. BP Fluor 405 acid is also often used for control experiments, and for calibration.
|
-
- HY-D2738
-
|
|
Fluorescent Dyes/Probes
|
|
BP Fluor 532 NHS ester is an amine reactive, yellow-emitting dye routinely used to label proteins or antibodies through primary amines (Lys), amine-modified oligonucleotides, and other amine-containing biomolecules. The labeling occurs most efficiently at pH 7-9 and forms a stable, covalent amide bond.
BP Fluor 532 is a bright yellow-fluorescent dye with pH insensitive emission from pH 4 to pH 10. The excitation of BP Fluor 532 is ideally suited for the frequency-doubled Nd:YAG laser line. BP Fluor 532 can be conjugated to a variety of antibodies, peptides, proteins, tracers, and amplification substrates, and is often used for the generation of stable signals in imaging and flow cytometry.
|
-
- HY-W800701
-
|
|
Fluorescent Dyes/Probes
|
|
BP Fluor 546 DBCO is an azide-reactive probe that can be used for imaging azide-tagged biomolecules via a copper-free click reaction. The DBCO moiety reacts with azides to form a stable triazole and does not require a Cu-catalyst or elevated temperatures. In applications where the presence of copper is a concern, BP Fluor 546 DBCO is an ideal alternative to copper-requiring fluorescent alkynes.
BP Fluor 546 is a water-soluble, pH-insensitive (from pH 4-10), orange-fluorescent dye with absorption and emission maxima at 554 and 570 nm, respectively. It can be used with the 488 nm and 532 nm laser lines. BP Fluor 546 dye conjugates to a variety of antibodies, peptides, proteins, tracers, and amplification substrates, which are often used for generating stable signals in imaging and flow cytometry.
|
| Cat. No. |
Product Name |
Type |
-
- HY-161564
-
|
|
Biochemical Assay Reagents
|
|
T4/OVA is a conjugate of T4 peptide (thyroxine T4) and ovalbumin. T4/OVA is a altered peptide, which can be used to stimulate OT-I CD8+ T cells .
|
-
- HY-150241
-
|
|
Drug Delivery
|
|
DOPE-NHS is a linker. DOPE-NHS can be used for peptides to be conjugated to exosomes and possibly other membrane-based nanoparticles. DOPE-NHS can be used for drug delivery .
|
-
- HY-163551
-
|
|
Biochemical Assay Reagents
|
|
The BNP peptide/KLH is an antigen-adjuvant conjugate formed by linking BNP peptide (human brain natriuretic peptide) with keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or damage the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-172273B
-
|
|
Drug Delivery
|
|
DSPE-PEG5000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG5000-M2pep can be used for drug delivery .
|
-
- HY-172273A
-
|
|
Drug Delivery
|
|
DSPE-PEG2000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG2000-M2pep can be used for drug delivery .
|
-
- HY-172273
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG1000-M2pep can be used for drug delivery .
|
-
- HY-172273C
-
|
|
Drug Delivery
|
|
DSPE-PEG3400-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG3400-M2pep can be used for drug delivery .
|
-
- HY-172270D
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-172270C
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-172270
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-172270A
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-100374G
-
|
|
Biochemical Assay Reagents
|
|
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
|
-
- HY-13631EG
-
|
MC-GGFG-DXD (GMP)
|
Biochemical Assay Reagents
|
|
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
|
-
- HY-140739
-
|
|
Drug Delivery
|
|
DSPE-PEG2000-Maleimide is a phospholipid-PEG conjugate. DSPE-PEG2000-Maleimide utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles. DSPE-PEG2000-Maleimide covalently couples to the sulfhydryl (-SH) of ligands (such as antibodies, peptides, or proteins) via thiol-maleimide click chemistry, giving the particles targeting capabilities. DSPE-PEG2000-Maleimide can be used in the researches of breast cancer, lymphoma, and inherited retinal degeneration .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4198
-
-
- HY-P5334A
-
|
|
Tau Protein
|
Neurological Disease
|
|
AADvac 1 TFA is an active tau peptide vaccine for Alzheimer's disease research. AADvac 1 TFA is composed of a regulatory peptide 294KDNIKHVPGGGS 305 that drives tau oligomerization conjugated to Aplysia hemocyanin (KLH) and formulated with aluminum hydroxide .
|
-
- HY-P10736
-
|
|
GCGR
|
Metabolic Disease
|
|
AMG133 peptide payload is a GLP-1 agonist that can be used as a peptide linker conjugate of Maridebart cafraglutide (AMG133) (HY-164535) .
|
-
- HY-106244A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-106244
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P1043A
-
|
|
Aminopeptidase
|
Cancer
|
|
NGR peptide Trifluoroacetatecontaining the Asn-Gly-Arg (NGR) motif. NGR peptide Trifluoroacetate binds to APN/CD13. NGR peptide Trifluoroacetate is directly conjugated to imaging agents that can be used for tumor imaging .
|
-
- HY-P10946
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
FAP targeting peptide-PEG2 conjugate (Example A1) is the peptide (HY-P10945) and linker conjugate of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand .
|
-
- HY-P11051
-
|
|
Peptides
|
Cancer
|
|
GE11, Cys Conjugated is a peptide conjugate. GE11, Cys Conjugated consists of a GE11 (HY-P10128) with a GGGGC sequence. GE11, Cys Conjugated can be used for synthesis of stimuli-responsive peptide nanomaterials (SRPNs) for photoacoustic imaging and cancer therapy, such as triple-negative breast cancer (TNBC)
|
-
- HY-P10741
-
-
- HY-P11050
-
|
|
Peptides
|
Cancer
|
|
SP94 peptide, Cys conjugated is a hepatocellular carcinoma (HCC)-targeting peptide. SP94 peptide, Cys conjugated can be used for synthesis of stimuli-responsive peptide nanomaterials (SRPNs) like platinum nanocluster assemblies (PT-NA) and it promotes the entry of PT-NA into HCC cells by mediating endocytosis. SP94 peptide, Cys conjugated can be used for cancers research .
|
-
- HY-P1043
-
|
|
Aminopeptidase
|
Cancer
|
|
NGR peptide containing the Asn-Gly-Arg (NGR) motif. NGR peptide binds to APN/CD13. NGR peptide is directly conjugated to imaging agents that can be used for tumor imaging .
|
-
- HY-P10183
-
-
- HY-P10645
-
|
|
Peptides
|
Cardiovascular Disease
|
|
T9 peptide (SKTFNTHPQSTP) is a muscle targeting peptide. T9 peptide binds strongly to C2C12 myoblasts. T9 peptide is capable of increased specificity for the heart and quadriceps muscles if conjugated to oligonucleotides without a similar effect in targeting to the kidney, liver, and diaphragm.
|
-
- HY-P5888
-
|
Myr‐PKCɛ-
|
PKC
|
Inflammation/Immunology
|
|
PKCε inhibitor peptide,myristoylated (Myr‐PKC -) is a cell permeable myristic acid conjugated PKC peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs) .
|
-
- HY-P3669
-
-
- HY-P10736A
-
|
|
GCGR
|
Metabolic Disease
|
|
AMG133 peptide payload TFA is the TFA salt form of AMG133 peptide payload (HY-P10736). AMG133 peptide payload TFA is a GLP-1 agonist that can be used for synthesis of Maridebart cafraglutide (AMG133) (HY-164535) as a peptide linker conjugate .
|
-
- HY-P10641
-
|
|
Peptides
|
Cardiovascular Disease
|
|
Heart-homing peptide is a peptide, CRPPR. CRPPR is a linear peptide containing arginine that has been identified as a heart-homing peptide owing to its ability to specifically bind to heart endothelium, and cysteine-rich protein-2 (CRIP-2) has been proposed as the receptor. Heart-homing peptide can be used for conjugating liposomes .
|
-
- HY-164166
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Fmoc-Sar-Sar-Sar-OH is a small molecule polypeptide composed of four sarcosine residues, in which the N-terminus of the peptide chain is protected by Fmoc. Fmoc-Sar-Sar-Sar-OH can be used for peptide synthesis or synthesis of drug-peptide ligand conjugates .
|
-
- HY-P10184
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
CD36 Peptide P (93-110), Cys conjugated is a Cys labelled CD36 Peptide, and can block binding of CD36 to immobilized thrombospondin and partially inhibited collagen-induced platelet aggregation .
|
-
- HY-P10790
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Breast cancer targeting peptide 18–4 is a KRT1 receptor-targeting peptide, with a Kd of 0.98 μM. The amino acid sequence of Breast cancer targeting peptide 18–4 is WxEAAYQrFL, and it is an analogue of P160 peptide (HY-P10789). When covalently conjugated with the anticancer peptide MccJ25, Breast cancer targeting peptide 18–4 significantly increases the cellular uptake of MccJ25 in breast cancer cells and enhances its anticancer activity. The covalent conjugate exhibits IC50 values of 14.2, 20, and 25 μM against MCF-7, MDA-MB-435, and MDA-MB-435-MDR cells, respectively .
|
-
- HY-P5334
-
|
|
Peptides
|
Neurological Disease
|
|
AADvac 1 is an active tau peptide vaccine for Alzheimer's disease research. AADvac 1 is composed of a regulatory peptide 294KDNIKHVPGGGS 305 that drives tau oligomerization conjugated to Aplysia hemocyanin (KLH) and formulated with aluminum hydroxide .
|
-
- HY-P10870
-
|
|
Peptide-Drug Conjugates (PDCs)
FGFR
Apoptosis
|
Cancer
|
|
Pep1-DNP conjugate 9 is a functionalized peptide which is composed of the DNP-Hapten and the FGFR1 binding peptide. Pep1-DNP conjugate 9 exhibits good affinity to FGFR1 with KD of 5.01 μM. Pep1-DNP conjugate 9 recruits anti-DNP antibodies to the surface of FGFR1-positive cells, inhibits the FGF2-induced proliferation in rat skeletal myoblast cells, and induces apoptosis. Pep1-DNP conjugate 9 exhibits antitumor efficacy in mouse models .
|
-
- HY-P3815
-
|
|
Casein Kinase
|
Others
|
|
Casein Kinase 2 Substrate Peptide is a common CK2 substrate peptide. Casein Kinase 2 Substrate Peptide is synthesized with its C-terminus conjugated to 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS). Casein Kinase 2 Substrate Peptide can be used for protein kinase CK2 activity determination .
|
-
- HY-P10559
-
|
|
Bacterial
|
Infection
|
|
(RXR)4XB is a cell-penetrating peptide, that binds the phosphorodiamidate morpholino oligomers (PMOs), forms peptide-conjugated PMOs (PPMOs), and improves the delivery of PMO into bacterial cells. (RXR)4XB-PMO conjugate prevents the formation of biofilms, inhibits Pseudomonas aeruginosa with MIC50 of 0.5 to 16 μM, and reduces the bacterial burden in mouse acute pneumonia models .
|
-
- HY-P10701
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
Cancer
|
|
Q11 peptide is a β-sheet-forming peptide that plays an important role in self-assembly and targeted applications. As a scaffold peptide, Q11 peptide can display immunogenic epitopes and is widely used in peptide-based immune vaccine research. Additionally, Q11 peptide can be conjugated with MUC1 glycopeptides for the study of self-assembling, adjuvant-free MUC1 glycopeptide vaccines. Q11 peptide holds great potential for research in the field of cancer immunology .
|
-
- HY-P10641A
-
|
|
Peptides
|
Cardiovascular Disease
|
|
Heart-homing peptide TFA is a Pentapeptide, CRPPR. CRPPR is a linear peptide containing arginine that has been identified as a heart-homing peptide owing to its ability to specifically bind to heart endothelium, and cysteine-rich protein-2 (CRIP-2) has been proposed as the receptor. Heart-homing peptide TFA can be used for conjugating liposomes .
|
-
- HY-P10648
-
|
HER2-targeting Peptide
|
EGFR
|
Cancer
|
|
Herceptide (HER2-targeting peptide) is a HER2-targeting peptide, and can be further conjugated to the near-infrared fluorescent dye indocyanine green (HY-D0711) (ICG) for developing theranostic agents .
|
-
- HY-P10559A
-
|
|
Bacterial
|
Infection
|
|
(RXR)4XB TFA is a cell-penetrating peptide, that binds the phosphorodiamidate morpholino oligomers (PMOs), forms peptide-conjugated PMOs (PPMOs), and improves the delivery of PMO into bacterial cells. (RXR)4XB TFA-PMO conjugate prevents the formation of biofilms, inhibits Pseudomonas aeruginosa with MIC50 of 0.5 to 16 μM, and reduces the bacterial burden in mouse acute pneumonia models .
|
-
- HY-P10646
-
|
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
Muscle homing peptide M12 can preferentially bind to surface protein of muscle cells. Muscle homing peptide M12 mediates enhanced cellular uptake of nanoparticles (NPs) in myoblasts in vitro. Muscle homing peptide M12 is covalently conjugated to PLGA-PEG NPs via the N-terminal α-amino groups of peptides using the N-hydroxysuccinimide ester reaction .
|
-
- HY-P10794
-
|
|
Peptides
|
Cancer
|
|
LH2 peptide is a pH-responsive cell-penetrating peptide dimer with the amino acid sequence LHHLCHLLHHLCHLAG. It can increase its uptake in tumor cells under weakly acidic conditions (such as the tumor microenvironment) through the protonation of histidine residues (pKa approximately 6). When conjugated with the anticancer drug Paclitaxel (HY-B0015), the PTX-LH2 conjugate showed superior tumor suppression effects compared to paclitaxel alone in a subcutaneous breast tumor model. The LH2 peptide holds potential as a drug delivery vehicle in cancer research .
|
-
- HY-P10895
-
|
|
Biochemical Assay Reagents
|
Others
|
|
HR97 TFA is a cell-penetrating peptide that can be combined with engineered melanin to prepare eye drops HR97-SunitiGel. The peptide-drug conjugate in HR97-SunitiGel can provide sustained ocular drug delivery .
|
-
- HY-P1116
-
PBP10
1 Publications Verification
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
PBP10 is a cell permeable and selective gelsolin-derived peptide inhibitor of formyl peptide receptor 2 (FPR2) over FPR1 . PBP10 is a 10-AA peptide with rhodamine conjugated at its N terminus, exerts bactericidal activity against gram-positive and gram-negative bacteria and limits microbial-induced inflammatory effects .
|
-
- HY-P1116A
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
PBP10 is a cell permeable and selective gelsolin-derived peptide inhibitor of formyl peptide receptor 2 (FPR2) over FPR1 . PBP10 is a 10-AA peptide with rhodamine conjugated at its N terminus, exerts bactericidal activity against gram-positive and gram-negative bacteria and limits microbial-induced inflammatory effects .
|
-
- HY-P1351
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Angiopep-2-cys is a conjugate of Angiopep-2 hydrochloride (HY-P2341) and cysteine. Angiopep-2 hydrochloride is a brain peptide vector. The conjugation of anticancer agents with the Angiopep-2 peptide vector could increase their efficacy in the treatment of brain cancer .
|
-
- HY-P10293
-
|
|
Thrombin
Peptides
|
Others
|
|
NQEQVSP, a fibrin-binding protein-derived peptide (FBP), is a factor XIIIa substrate. NQEQVSP can be recognized by factor XIII and is enzymatically conjugated into fibrin during polymerization .
|
-
- HY-P2218
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Cancer
|
|
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5877
-
|
|
PKC
|
Inflammation/Immunology
|
|
PKC(85–92),Myristoylated is a cell permeable myristic acid conjugated PKC peptide activator that enhances NO release in cultured human umbilical vein endothelial cells (HUVECs) .
|
-
- HY-P10444
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Cancer
|
|
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P4091A
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
LSD acetate is a peptide. LSD acetate can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD acetate can reduce the number of tumor lymphatics. LSD acetate can be used in the research of targeted therapy and diagnosis of tumor lymphatics .
|
-
- HY-P4091
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics .
|
-
- HY-P4084A
-
|
|
Peptides
|
Others
|
|
KLA seq acetate is a cell membrane-penetrating α-helical amphipathic model peptide. KLA seq acetate conjugates peptide nucleic acids (PNAs) for delivery to mammalian cells. KLA seq acetate covalently links targeted mRNA and fluorescein to form a delivery system that has low re-export and is less resistant to serum effects .
|
-
- HY-P11205
-
|
Cys-txCD47
|
CD47
Reactive Oxygen Species (ROS)
Thrombopoietin Receptor
|
Inflammation/Immunology
Cancer
|
|
Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca + accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death .
|
-
- HY-P5439
-
|
|
PKC
MARCKS
|
Others
|
|
Epsilon-V1-2, Cys-conjugated is a biological active peptide. (This peptide is the εPKC specific inhibitor. Its inhibitory activity is based on εPKC translocation and MARCKS phosphorylation. This peptide interferes with εPKC interaction with the anchoring protein εRACK. This peptide contains a cysteine residue added to the C-terminus for potential S-S bond formation with a carrier protein.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)
|
-
- HY-P4154
-
|
ALM-488
|
Fluorescent Dye
|
Neurological Disease
Cancer
|
|
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
|
-
- HY-P10773
-
-
- HY-P10786
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
LinTT1 peptide is a tumor-penetrating peptide with the amino acid sequence AKRGARST. LinTT1 peptide targets peritoneal carcinoma (PC) by binding to the p32 (gC1qR) receptor. It can conjugate with iron oxide nanoworms (NWs) to form a nanocarrier. This nanocarrier is taken up by peritoneal carcinoma cells in vitro and enters the mitochondria; it also exhibits significant tumor targeting and penetration effects in mice. Moreover, LinTT1-functionalized nanocarriers, combined with the pro-apoptotic peptide [D(KLAKLAK)2], show significant tumor suppression in a mouse peritoneal tumor model. LinTT1 peptide holds promise as a delivery carrier for peritoneal cancer research .
|
-
- HY-P10757
-
-
- HY-153549
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Others
|
|
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium ( 68Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P1188
-
|
|
Integrin
|
Cancer
|
|
LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC can be used to detect α4β1 integrin affinity .
|
-
- HY-P5891
-
|
|
PKC
|
Cardiovascular Disease
|
|
TAT-SAMβA is the peptide consist of RNAENFDRF (SAMβA; HY-P3429) conjugated to the cell penetrating TAT protein-derived peptide TAT47–57. TAT-SAMβA is a selective antagonist of Mfn1-βIIPKC association. TAT-SAMβA protects mouse embryonic fibroblast cells (MEFs) against oxidative stress-induced cytotoxicity .
|
- HY-P5320
-
|
|
Apoptosis
|
Others
|
|
TAT-BH4 (Bcl-xL) localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 can be used for research of diseases caused by accelerated apoptosis .
|
- HY-P1188A
-
|
|
Integrin
|
Cancer
|
|
LDV-FITC TFA, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC TFA binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC TFA can be used to detect α4β1 integrin affinity .
|
- HY-P10792
-
|
|
EGFR
|
Cancer
|
|
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .
|
- HY-P5021
-
|
c(RGDfE)
|
Biochemical Assay Reagents
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) (c(RGDfE)) is a cyclic RGD peptide that serves as a conjugated multifunctional nanodrug delivery system to target Gemcitabine to pancreatic cancer cells. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) can be used in cancer research .
|
- HY-P5320A
-
|
|
Apoptosis
|
Others
|
|
TAT-BH4 (Bcl-xL) TFA is localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 TFA can be used for research of diseases caused by accelerated apoptosis .
|
- HY-P3732
-
|
|
Integrin
|
Cancer
|
|
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .
|
- HY-P4095
-
|
|
CXCR
|
Cancer
|
|
NoxaBH3 is a cysteine-based cross-linked peptide with increased cell permeability and higher inhibitory activity against Mcl-1. NoxaBH3 binds to the endogenous CXCR4 ligand to produce ubiquitin-Noxabh3 conjugate. NoxaBH3 is then delivered to cancer cells .
|
- HY-P3429
-
|
|
PKC
|
Cardiovascular Disease
|
|
SAMβA is conjugated to the cell permeable peptide TAT47-57. SAMβA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats .
|
- HY-113003
-
|
γ-Glutamylglutamine; γ-Glu-Gln
|
Peptides
|
Others
Cancer
|
|
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .
|
- HY-P10782
-
|
|
Peptide-Drug Conjugates (PDCs)
|
Cancer
|
|
Pt(IV)-M13 is a BBB-penetrable Platinum (IV) prodrug-perfluoroaryl macrocyclic peptide conjugate. Pt(IV)-M13 is cytotoxic to glioma stem cells and increases uptake of platinum in the brain. Pt(IV)-M13 can be used in the study of glioblastoma .
|
- HY-125586
-
|
|
DNA/RNA Synthesis
ADC Payload
|
Cancer
|
|
β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic RNA polymerase II and III. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .
|
- HY-W729138
-
|
|
ADC Linker
|
Others
|
|
Fmoc-D-homoArg(Et)2-OH (hydrochloride) is a Fmoc-protected derivative of D-Homoarginine (HArg) that renders peptides and proteins resistant to proteolysis by trypsin. Fmoc-D-homoArg(Et)2-OH (hydrochloride) can be used as a cleavable ADC linker to synthesize antibody-drug conjugates (ADCs) .
|
- HY-P10762
-
|
CBP-1008; LDC 10B
|
Peptide-Drug Conjugates (PDCs)
Folate Receptor (FR)
TRP Channel
|
Cancer
|
|
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
|
- HY-P3429A
-
|
|
PKC
|
Cardiovascular Disease
|
|
SAMβA TFA is conjugated to the cell permeable peptide TAT47-57. SAMβA TFA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA TFA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats .
|
- HY-P10775
-
|
|
Peptide-Drug Conjugates (PDCs)
MMP
|
Cancer
|
|
BT1769 is a MT1-MMP-targeted (KD = 3.35 nM) Bicycle toxin conjugate. BT1769 can be used in the study for osteosarcoma. BT1769 consists of a novel bicyclic targeting peptide that selectively binds MT1-MMP; a cytotoxin MMAE; and an enzymatically cleavable dipeptide linker .
|
- HY-P10307
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Bacterial
|
Infection
|
|
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ 68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
- HY-P5297
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Cancer
|
|
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
- HY-P10846
-
|
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
|
HYNIC-CTP is a conjugate of HYNIC and CTP (cardiac-targeting peptide). HYNIC-CTP can bind with the radionuclide 99mTc through HYNIC acting as a chelator, forming 99mTc-HYNIC-CTP. 99mTc-HYNIC-CTP is specifically taken up by the heart and used for cardiac imaging, thereby facilitating research into heart diseases .
|
- HY-P6351
-
|
|
Integrin
|
Cancer
|
|
c(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with DOTA chelator. The Lu(III) complex of c(avb6)-DOTA TFA has a comparable affinity for αvβ6 integrin (IC50=0.8 nM) and can be used as a tumor diagnostic .
|
- HY-P10740
-
|
|
Peptide-Drug Conjugates (PDCs)
Antifolate
|
Cancer
|
|
CBP-1018 is a PDC (peptide drug conjugate) consisting of a dual targeting FRα/prostate-specific membrane antigen (PSMA) ligand (blue part) coupled to Monomethyl auristatin E (HY-15162) (red part) via a linker (HY-78738) (black part). CBP-1018 is expected to be used in breast cancer research .
|
- HY-P10770
-
|
|
Peptide-Drug Conjugates (PDCs)
E-Selectin
|
Cardiovascular Disease
Cancer
|
|
P-ESBP-DOX is a HPMA copolymer-drug conjugate, which is consistituted of the E-selectin binding peptide and the Doxorubicin (HY-15142). P-ESBP-DOX exhibits cytotoxicity against TNFα-activated human vascular endothelial cells IVECs with an IC50 of 0.28 μM. P-ESBP-DOX can be used in research about tumor vasculature .
|
- HY-P10760
-
|
|
Peptide-Drug Conjugates (PDCs)
|
Cancer
|
PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .
|
- HY-P10356
-
|
|
TRP Channel
|
Others
|
|
T100-Mut is a cell-permeable peptide whose N-terminus is conjugated with a myristoylated group to enable T100-Mut to penetrate and localize to the inner side of the plasma membrane, thus mimicking the topology of Tmem100-3Q. T100-Mut can alleviate TRPA1-mediated pain .
|
- HY-P10153
-
|
|
Peptides
|
Others
|
|
gH625 is a cell-penetrating viral peptide which is a part of glycoprotein H of Herpes simplex virus type I. gH625 is able to cross the cell membrane and to transport many conjugated cargoes into the cytosol. gH625 is permeable to the blood-brain barrier (BBB) and can enter the rat brain in vivo without toxic effects. gH625 can be used for siRNA delivery research .
|
- HY-P4073
-
|
GRN1005; Paclitaxel trevatide
|
Peptide-Drug Conjugates (PDCs)
LDLR
|
Cancer
|
|
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .
|
- HY-P10567
-
|
|
Peptides
|
Others
|
|
Pip6a is an arginine-rich cell-penetrating peptide. Pip6a has the ability to deliver associated cargoes across the plasma and endosomal membranes and is stable to serum proteolysis. Pip6a is composed of a hydrophobic core region flanked on each side by arginine-rich domains containing β-alanine and aminohexanoyl spacers. Pip6a-conjugated morpholino phosphorodiamidate oligomer (PMO) dramatically enhanced antisense oligonucleotide (ASO) delivery into striated muscles of myotonic dystrophy (DM1) mice .
|
- HY-P4742A
-
|
6-FAM-AEEAC-SHK TFA
|
Biochemical Assay Reagents
Potassium Channel
|
Neurological Disease
|
|
6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA (6-FAM-AEEAC-SHK TFA) is a peptide neurotoxin conjugated with a fluorescent marker. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can block voltage-gated potassium channels (kv1.1 and kv1.2) to prolong the duration of action potentials, thereby affecting the conduction of neural signals. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can be used in neuroscience research .
|
- HY-P10947
-
|
|
Epigenetic Reader Domain
YAP
|
Cancer
|
|
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 + tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .
|
- HY-P10761
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Carbonic Anhydrase
|
Cancer
|
|
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC50 for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
- HY-P10446
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Epigenetic Reader Domain
|
Cancer
|
|
TAT-PiET-PROTAC is a proteolysis-targeting chimera (PROTAC)-modified TAT-PiET (HY-P10445). TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4. TAT-PiET-PROTAC can disrupt the interaction between the breast cancer oncogene BRD4/JMJD6 and inhibit the growth of breast cancer cells. TAT-PiET-PROTAC also resists the endocrine resistance of ERα-positive breast cancer cells and is a potential inhibitor of breast cancer . TAT-PiET-PROTAC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
- HY-P11018
-
|
|
Peptide-Drug Conjugates (PDCs)
Ephrin Receptor
|
Cancer
|
|
(123B9)2-L2-PTX is an EphA2-agonistic peptide-drug conjugate (PDC). (123B9)2-L2-PTX consists of a dimeric 123B9 (HY-P10579) and Paclitaxel (HY-B0015). (123B9)2-L2-PTX significantly reduces circulating tumor cells and inhibits lung tumor metastasis in breast-cancer-Metastasis mice model. (123B9)2-L2-PTX can be used for cancers research, such as melanomas and ovarian and breast cancers .
|
-
- HY-K0219
-
1 Publications Verification
|
|
MCE High-Affinity Iodoacetyl Agarose, a 4% highly cross-linked agarose reagent coupled with a derivative of iodoacetic acid, is ideal for conjugating sulfhydryl-containing peptide or protein for subsequent affinity purification.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99924
-
|
|
GHR
|
Others
|
|
Efpegsomatropin is a human growth hormone-Fc conjugate peptide. Efpegsomatropin can be used for various biochemical studies.
|
-
- HY-P99527
-
|
ACC-001; PF 05236806
|
Amyloid-β
|
Neurological Disease
|
|
Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .
|
-
- HY-P99565
-
|
ARENEGYR; NGR-TNF; NGR-hTNF
|
TNF Receptor
|
Cancer
|
|
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment .
|
-
- HY-P99881
-
|
ABBV 176
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Rolinsatamab talirine (ABBV 176) is an antibody-drug conjugate (ADC) targeting prolactin receptor (PRLR). Rolinsatamab talirine consists of rolinsatamab (HY-P99238), an enzymatically cleavable peptide linker, and SGD-1882 (HY-101127) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-113003
-
-
-
- HY-N15721
-
|
Trp-CA
|
Triterpenes
Structural Classification
Terpenoids
Source classification
Endogenous metabolite
|
Orphan GPCR
|
|
Tryptophan-cholic acid (Trp-CA) is a microbial amino-acid-conjugated bile acid, serving as an endogenous ligand and agonist of the orphan G protein-coupled receptor (GPCR) MRGPRE. Tryptophan-cholic acid activates MRGPRE, promoting the secretion of glucagon-like peptide-1 (GLP-1) through the Gs-cAMP and β-arrestin-1-ALDOA signaling pathways, thereby improving glucose tolerance in diabetic mice. Tryptophan-cholic acid is promising for research of type 2 diabetes .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-13631ES4
-
|
|
|
Deruxtecan-d5 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
-
- HY-13631ES
-
|
|
|
Deruxtecan-d4 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
-
- HY-13631ES3
-
|
|
|
Deruxtecan-d2 is the deuterium labeled Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
-
- HY-13631ES2
-
|
|
|
Deruxtecan-d4-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-158199
-
|
|
|
BCN
|
|
BCN-HS-PEG2-bis(PNP) (Compound 62) is a p-nitrophenyl-containing ADC linker that can be used to further couple ADC cytotoxins with peptide linkers. BCN-HS-PEG2-bis(PNP) can conjugate with vc-PABC-MMAE (HY-15162) to form Drug-Linker Conjugates for ADC .
|
-
- HY-153486
-
|
|
|
Azide
|
|
N3-VC-PAB-PNP is the intermediate of bicyclic peptide ligand STING conjugates . N3-VC-PAB-PNP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-150241
-
|
|
|
Phospholipids
|
|
DOPE-NHS is a linker. DOPE-NHS can be used for peptides to be conjugated to exosomes and possibly other membrane-based nanoparticles. DOPE-NHS can be used for drug delivery .
|
-
- HY-132604A
-
|
ARO-AAT sodium
|
|
siRNAs
siRNA drugs
|
|
Fazirsiran sodium is a second-generation RNAi agent. Fazirsiran sodium consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran sodium can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.
|
-
- HY-140739
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-Maleimide is a phospholipid-PEG conjugate. DSPE-PEG2000-Maleimide utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles. DSPE-PEG2000-Maleimide covalently couples to the sulfhydryl (-SH) of ligands (such as antibodies, peptides, or proteins) via thiol-maleimide click chemistry, giving the particles targeting capabilities. DSPE-PEG2000-Maleimide can be used in the researches of breast cancer, lymphoma, and inherited retinal degeneration .
|
-
- HY-172273B
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG5000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG5000-M2pep can be used for drug delivery .
|
-
- HY-172273A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG2000-M2pep can be used for drug delivery .
|
-
- HY-172273
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG1000-M2pep can be used for drug delivery .
|
-
- HY-172270
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-172270A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-132604
-
|
ARO-AAT
|
|
siRNAs
siRNA drugs
|
|
Fazirsiran (ARO-AAT) is a second-generation RNAi agent. Fazirsiran consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
